Clinical Trials Browser

Phase 2/3 × INDUSTRY × Whole-Body Irradiation × Clear all

NCT07157514 2025-09-10

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute